Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.

ImmunityBio, Inc.

Summary

This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.

Eligibility

Age range: 18–70 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Age ≥ 18 and \< 70 years. * Enrolled or willing to enroll and complete at least 1 visit in the UCSF Long-term Impact of Infection with Novel Coronavirus study. Any adult who has been infected with SARS-CoV-2 or has ever received or is eligible to receive a SARS-CoV-2 vaccination, and who is able to provide written informed consent, is eligible to participate in LIINC. * History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and/or a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Written proof of the…

Interventions

Drug
N-803 (IL-15 Superagonist)
N-803 administered subcutaneously.

Location

University of California - San Francisco
San Francisco, California
Emily.Fehrman2@ucsf.edu (650) 761-2163

Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions